At present, the company's quadrivalent influenza virus subunit vaccine (for ages 3 and above) has been launched for sale. The quadrivalent influenza virus subunit vaccine (6-35 months old) has completed phase III clinical trials and entered the NDA registration and production stage. The 23 valent pneumococcal polysaccharide vaccine has completed phase I clinical trials, and the freeze-dried human rabies vaccine (human diploid cell) is currently undergoing phase I clinical trials. Multiple academic achievements have been published in the internationally authoritative journal Vaccine and have been continuously cited in the recent annual "Technical Guidelines for Influenza Vaccination in China".
The company's No.1 production park covers an area of 69 acres and has a building area of 80000 square meters. It is equipped with production workshops, central laboratories, animal rooms, as well as supporting facilities such as research and development buildings, power centers, and warehousing centers that meet national standards. We have completed the construction of GMP production lines for influenza liquid and formulation workshops with international standards, and obtained the vaccine Production License and Experimental Animal Use License; More than 100 acres of newly added land in Phase II/III will be used for the industrial production of all pipeline varieties. The company has obtained 23 national registered trademarks. Has won honors such as "Potential Unicorn Enterprise in Jiangsu High tech Industrial Development Zone in 2020", "Gazelle Enterprise in Jiangsu High tech Zone", and "Top Ten Industrial Transformation and Innovation Investment Projects in Taizhou City".
At present, the company's team has over 600 members, with core team members being professional talents from the fields of domestic and foreign biological product production and research and development, with years of experience in vaccine research and development, production, testing, and management. The company has received 1 national level talent support, 1 Jiangsu Province "Double Innovation Talent" project, 3 Jiangsu "113 Talents" high-level innovation talent plans, 1 high-level entrepreneurial talent plan, and 1 special contribution talent project support.
Not simply copying, targeting international trends, and creating innovative vaccines are the project principles of Ab&B Bio-Tech. Caring for life and safeguarding health are the mission of Ab&B Bio-Tech!Ab&B Bio-Tech will carry forward the spirit of innovation, pragmatism, self-discipline, integrity, and persistent struggle, make unremitting efforts, and enable China to use global innovative vaccines and the world to use high-quality Chinese vaccines!